盐替代对心血管事件和死亡的影响
该研究为开放标签、整群随机试验,纳入中国农村600个村庄的20995人,参与者有卒中史或年龄≥60岁且患高血压。村庄按1:1随机分为盐替代品组(质量比75%氯化钠和25%氯化钾)和常规盐组(100%氯化钠)。平均随访4.74年,盐替代品组卒中、主要心血管事件和全因死亡率均低于常规盐组,高钾血症相关严重不良事件率无显著差异。
要点
- 适用人群:有卒中史或年龄≥60岁且患高血压者,盐替代品(75%氯化钠和25%氯化钾)降低卒中(RR 0.86,95%CI 0.77-0.96,P=0.006)。
- 主要心血管事件率盐替代品组49.09 vs 常规盐组56.29/1000人年(RR 0.87,95%CI 0.80-0.94,P<0.001)。
- 全因死亡率盐替代品组39.28 vs 常规盐组44.61/1000人年(RR 0.88,95%CI 0.82-0.95,P<0.001)。
- 高钾血症相关严重不良事件率无显著增加(3.35 vs 3.30/1000人年,RR 1.04,95%CI 0.80-1.37,P=0.76)。
- 该试验为开放标签整群随机,干预在村庄层面,个体依从性未单独报告。
适用人群与场景
- 纳入:中国农村600个村庄中,有卒中史或年龄≥60岁且患高血压的20995人;平均年龄65.4岁,49.5%女性,72.6%有卒中史,88.4%有高血压史。
- 排除人群:原文未提及。
- 场景:社区/村庄层面,非急诊或ICU床旁急性期干预。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 干预组使用盐替代品(质量比75%氯化钠和25%氯化钾),对照组继续使用常规盐(100%氯化钠);原文未提及剂量、频次或疗程。
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的情况。
研究设计与关键结果
- 研究类型:开放标签、整群随机试验,纳入中国农村600个村庄的20995人,平均随访4.74年。
- 干预与对照:盐替代品(75%氯化钠和25%氯化钾)vs 常规盐(100%氯化钠)。
- 主要终点卒中:29.14 vs 33.65事件/1000人年,RR 0.86(95%CI 0.77-0.96),P=0.006。
- 关键次要终点主要心血管事件:49.09 vs 56.29事件/1000人年,RR 0.87(95%CI 0.80-0.94),P<0.001;全因死亡:39.28 vs 44.61事件/1000人年,RR 0.88(95%CI 0.82-0.95),P<0.001。
- 安全性结局高钾血症相关严重不良事件:3.35 vs 3.30事件/1000人年,RR 1.04(95%CI 0.80-1.37),P=0.76。
证据类型、等级与局限
- 证据类型:开放标签、整群随机试验(RCT)。
- 证据等级或推荐强度:原文未提及。
- 局限:开放标签设计;整群随机在村庄层面;原文未报告个体依从性或盲法。
对床旁实践的改变
- 对于有卒中史或年龄≥60岁且患高血压的社区人群,可考虑使用含75%氯化钠和25%氯化钾的盐替代品以降低卒中、主要心血管事件和全因死亡风险;该证据不直接适用于急诊或ICU急性期患者,也不适用于原文未纳入的人群(如无卒中史且<60岁无高血压者)。
指南或共识出处
- 原文未提及指南或共识名称;试验注册号SSaSS ClinicalTrials.gov NCT02092090,资助方National Health and Medical Research Council of Australia。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Salt substitutes with reduced sodium levels and increased potassium levels have been shown to lower blood pressure, but their effects on cardiovascular and safety outcomes are uncertain.
METHODS: We conducted an open-label, cluster-randomized trial involving persons from 600 villages in rural China. The participants had a history of stroke or were 60 years of age or older and had high blood pressure. The villages were randomly assigned in a 1:1 ratio to the intervention group, in which the participants used a salt substitute (75% sodium chloride and 25% potassium chloride by mass), or to the control group, in which the participants continued to use regular salt (100% sodium chloride). The primary outcome was stroke, the secondary outcomes were major adverse cardiovascular events and death from any cause, and the safety outcome was clinical hyperkalemia.
RESULTS: A total of 20,995 persons were enrolled in the trial. The mean age of the participants was 65.4 years, and 49.5% were female, 72.6% had a history of stroke, and 88.4% a history of hypertension. The mean duration of follow-up was 4.74 years. The rate of stroke was lower with the salt substitute than with regular salt (29.14 events vs. 33.65 events per 1000 person-years; rate ratio, 0.86; 95% confidence interval [CI], 0.77 to 0.96; P = 0.006), as were the rates of major cardiovascular events (49.09 events vs. 56.29 events per 1000 person-years; rate ratio, 0.87; 95% CI, 0.80 to 0.94; P<0.001) and death (39.28 events vs. 44.61 events per 1000 person-years; rate ratio, 0.88; 95% CI, 0.82 to 0.95; P<0.001). The rate of serious adverse events attributed to hyperkalemia was not significantly higher with the salt substitute than with regular salt (3.35 events vs. 3.30 events per 1000 person-years; rate ratio, 1.04; 95% CI, 0.80 to 1.37; P = 0.76).
CONCLUSIONS: Among persons who had a history of stroke or were 60 years of age or older and had high blood pressure, the rates of stroke, major cardiovascular events, and death from any cause were lower with the salt substitute than with regular salt. (Funded by the National Health and Medical Research Council of Australia; SSaSS ClinicalTrials.gov number, NCT02092090.).
参考来源
- Neal B, Wu Y, Feng X, et al. Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med. 2021. PMID: 34459569. doi:10.1056/NEJMoa2105675
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。